Ascentage Pharma Group (AAPG) CFO submits initial insider ownership filing

Rhea-AI Filing Summary

ASCENTAGE PHARMA GROUP INTERNATIONAL filed an initial insider ownership report for Veet Misra, who serves as Chief Financial Officer. The available data lists Misra as the sole reporting person and shows no insider transactions or derivative positions in the excerpted information.

Key Terms

Chief Financial Officer, reporting person, Form 3

3 terms

Chief Financial Officer financial

"officer_title": "Chief Financial Officer""

A Chief Financial Officer (CFO) is the person in charge of a company's money and financial planning. They decide how to spend, save, and invest funds to help the company grow and stay stable. Their role is important because good financial decisions keep the company healthy and successful.

reporting person regulatory

""reportingPersons": [ { "name": "Misra Veet""

Form 3 regulatory

"INSIDER FILING DATA (Form 3):"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Misra Veet

(Last) (First) (Middle)

C/O ASCENTAGE PHARMA GROUP INC.

700 KING FARM BLVD., SUITE 510

(Street)

ROCKVILLE MARYLAND 20850

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
ASCENTAGE PHARMA GROUP INTERNATIONAL [ AAPG ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

This form is filed using a special power of attorney.

No securities are beneficially owned.

	Thomas J. Knapp	04/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Ascentage Pharma Group (AAPG) Form 3 for Veet Misra show?

The Form 3 identifies Veet Misra as Chief Financial Officer and a reporting person of Ascentage Pharma Group International. In the provided data, no insider transactions or derivative positions are listed, indicating this filing is primarily an initial ownership and role disclosure.

Who is the reporting person on Ascentage Pharma Group (AAPG) Form 3?

The reporting person is Veet Misra, designated as an officer of Ascentage Pharma Group International. The filing specifies Misra’s title as Chief Financial Officer, confirming their status as a senior executive subject to insider reporting requirements under Section 16 of U.S. securities laws.

Does the AAPG Form 3 for Veet Misra report any insider trades?

In the available data, the Form 3 for Veet Misra shows no reported insider buy, sell, acquire, or dispose transactions. The transaction summary fields are all zero, indicating the document excerpt functions as an initial ownership filing rather than a trade report.

Are any derivative securities reported for Veet Misra in the AAPG Form 3?

The derivative section in the provided data is empty, and the derivative transaction counts are zero. This means the excerpt does not show any options, warrants, or other derivative securities reported for Veet Misra in this initial ownership statement for Ascentage Pharma Group International.

What executive role does Veet Misra hold at Ascentage Pharma Group (AAPG)?

Veet Misra is listed as an officer of Ascentage Pharma Group International with the title Chief Financial Officer. This role typically includes overseeing financial reporting, planning, and controls, making Misra a key executive subject to ongoing insider disclosure obligations.